Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Immunol.

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1654374

This article is part of the Research TopicUnleashing Immunity against Cancer: New Horizons in ImmunotherapyView all 3 articles

SLAMF7 (CD319) enhances cytotoxic T-cell differentiation and sensitizes CD8⁺ T cells to immune checkpoint blockade

Provisionally accepted
Jan-Erik Sander  SanderJan-Erik Sander Sander1Irina  HanIrina Han1Lisette  FickenscherLisette Fickenscher1Jörg-Peter  SchmidtJörg-Peter Schmidt2Hartmut  KrollHartmut Kroll2Tereza  VosikovaTereza Vosikova3Martin  DurisinMartin Durisin3Holger  LingelHolger Lingel1Monika  C. Brunner-WeinzierlMonika C. Brunner-Weinzierl1*
  • 1Department of Experimental Pediatrics, Faculty of Medicine, University Hospital Magdeburg, Magdeburg, Germany
  • 2Institute for Transfusion Medicine Dessau, Red Cross Blood Transfusion Service NSTOB, Dessau-Roßlau, Germany
  • 3Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine, University Hospital Magdeburg, Magdeburg, Germany

The final, formatted version of the article will be published soon.

Tumors frequently evade immune destruction by impairing cytotoxic CD8 + T-cell responses, highlighting the need for strategies that restore T-cell functionality. Here, we identify SLAMF7 (CD319) as a key enhancer of human CD8 + T-cell responses against tumors. SLAMF7 expression is induced by pro-inflammatory signals such as IL-12 and CD28 co-stimulation. Agonistic SLAMF7 signaling, in synergy with TCR activation, is able to strongly induce T-cell activation and clonal expansion, a finding consistently observed in CD8 + T cells from healthy adults as well as derived from blood and tumor-draining lymph nodes of patients with head and neck squamous cell carcinoma (HNSCC). Moreover it drives a distinct differentiation programme characterized by elevated expression of key transcription factors Eomes and T-bet, leading to increased production of effector molecules such as Interferon , Granzyme B and Perforin. In contrast to CD28 costimulation, SLAMF7 activation also promotes serial killing potential via BTLA induction. In antigen-specific human models, SLAMF7 activation boosts CD8 + T-cell responses against the tumor-associated antigen NY-ESO-1, a key target in several cancers including HNSCC. Moreover, combining SLAMF7 activation with PD-1/PD-L1 immune checkpoint blockade synergistically enhances cytokine release and cytotoxic potential, highlighting its potential to overcome immunosuppression and reinvigorate antitumor immunity.

Keywords: SLAMF family, T-cell differentiation, Cytotoxicity, costimulation, Cancer, Immunotherapy, tumor rejection, Head and neck squamous cell carcinoma (HNSCC)

Received: 26 Jun 2025; Accepted: 31 Jul 2025.

Copyright: © 2025 Sander, Han, Fickenscher, Schmidt, Kroll, Vosikova, Durisin, Lingel and Brunner-Weinzierl. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Monika C. Brunner-Weinzierl, Department of Experimental Pediatrics, Faculty of Medicine, University Hospital Magdeburg, Magdeburg, Germany

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.